A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
Status:
Completed
Trial end date:
2020-05-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how fast galcanezumab gets into the blood stream and
how long it takes the body to remove it. Information about side effects will be collected.
The study is open to healthy Chinese participants. It will last up to about 24 weeks.